DK1639007T3 - VEGF-fælder og terapeutiske anvendelser deraf - Google Patents

VEGF-fælder og terapeutiske anvendelser deraf

Info

Publication number
DK1639007T3
DK1639007T3 DK04777335T DK04777335T DK1639007T3 DK 1639007 T3 DK1639007 T3 DK 1639007T3 DK 04777335 T DK04777335 T DK 04777335T DK 04777335 T DK04777335 T DK 04777335T DK 1639007 T3 DK1639007 T3 DK 1639007T3
Authority
DK
Denmark
Prior art keywords
therapeutic applications
vegf traps
vegf
traps
therapeutic
Prior art date
Application number
DK04777335T
Other languages
English (en)
Inventor
Thomas J Daly
James P Fandl
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33552268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1639007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1639007T3 publication Critical patent/DK1639007T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK04777335T 2003-06-30 2004-06-29 VEGF-fælder og terapeutiske anvendelser deraf DK1639007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/609,775 US7087411B2 (en) 1999-06-08 2003-06-30 Fusion protein capable of binding VEGF
PCT/US2004/021059 WO2005000895A2 (en) 2003-06-30 2004-06-29 Vegf traps and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK1639007T3 true DK1639007T3 (da) 2009-06-08

Family

ID=33552268

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08005360.6T DK1947118T3 (da) 2003-06-30 2004-06-29 VEGF-fælder og terapeutiske anvendelser deraf
DK04777335T DK1639007T3 (da) 2003-06-30 2004-06-29 VEGF-fælder og terapeutiske anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08005360.6T DK1947118T3 (da) 2003-06-30 2004-06-29 VEGF-fælder og terapeutiske anvendelser deraf

Country Status (29)

Country Link
US (4) US7087411B2 (da)
EP (2) EP1947118B1 (da)
JP (2) JP2007528708A (da)
KR (1) KR101131429B1 (da)
CN (1) CN1816566B (da)
AR (1) AR044938A1 (da)
AT (2) ATE486091T1 (da)
AU (1) AU2004252175B2 (da)
BR (1) BRPI0412125A (da)
CA (1) CA2529660C (da)
CY (2) CY1109204T1 (da)
DE (2) DE602004029833D1 (da)
DK (2) DK1947118T3 (da)
ES (2) ES2354847T3 (da)
HK (1) HK1082511A1 (da)
IL (2) IL172404A (da)
MX (1) MXPA05013641A (da)
MY (1) MY154826A (da)
NO (1) NO339766B1 (da)
NZ (2) NZ572107A (da)
PL (2) PL1639007T3 (da)
PT (2) PT1947118E (da)
RU (1) RU2376373C2 (da)
SI (2) SI1947118T1 (da)
TW (1) TWI330197B (da)
UA (2) UA105625C2 (da)
UY (1) UY28396A1 (da)
WO (1) WO2005000895A2 (da)
ZA (1) ZA200600157B (da)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
HUE027096T2 (en) * 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
MX2008001966A (es) * 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
US8329866B2 (en) * 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
PL1962895T3 (pl) * 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2008005290A2 (en) * 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
KR101580938B1 (ko) 2007-06-01 2015-12-30 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
EP2350264A4 (en) * 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATORY RESPIRATORY DISEASES
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CA2760687A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX347343B (es) 2010-07-28 2017-04-21 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
DK2601214T3 (da) 2010-08-06 2018-02-05 Genzyme Corp Vegf-antagonistsammensætninger og anvendelser deraf
US9518132B2 (en) * 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN106963946A (zh) 2011-08-19 2017-07-21 瑞泽恩制药公司 抗tie2抗体及其用途
EP2744508B1 (en) * 2011-08-19 2017-11-08 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CA3076725A1 (en) 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
CA2857168C (en) * 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2013138400A1 (en) 2012-03-14 2013-09-19 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
BR112015003459A2 (pt) 2012-08-20 2017-09-26 Gliknik Inc moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN104781280A (zh) 2012-11-13 2015-07-15 瑞泽恩制药公司 抗前动力蛋白受体(prokr)抗体及其使用
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
ES2898620T3 (es) 2013-03-14 2022-03-08 Regeneron Pharma Anticuerpos humanos contra GREM 1
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
WO2015058369A1 (en) * 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG11201606979TA (en) 2014-03-11 2016-09-29 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
WO2015142941A1 (en) 2014-03-17 2015-09-24 Avalanche Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
MX2017006312A (es) 2014-11-17 2017-08-21 Regeneron Pharma Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
SG11201707063TA (en) 2015-03-02 2017-09-28 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
CN115645543A (zh) 2015-03-27 2023-01-31 里珍纳龙药品有限公司 美登素类衍生物、其偶联物和使用方法
TW202336236A (zh) 2015-03-27 2023-09-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
KR20240067253A (ko) * 2015-04-23 2024-05-16 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
MA43987A (fr) 2015-05-12 2018-12-19 Regeneron Pharma Détermination de la pureté de protéine multimère
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
MX2018000587A (es) 2015-07-24 2018-05-02 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
HRP20220133T8 (hr) 2015-09-23 2022-05-13 Regeneron Pharmaceuticals, Inc. Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe
CA2998390A1 (en) 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017070866A1 (zh) * 2015-10-28 2017-05-04 黄志清 一种抗血管内皮生长因子的氧化石墨烯与其用途
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
PL3389636T3 (pl) 2015-12-16 2022-11-28 Regeneron Pharmaceuticals, Inc. Kompozycje i metody wytwarzania mikrocząstek białkowych
MX2018007613A (es) 2015-12-22 2018-09-21 Regeneron Pharma Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
SG11201806322QA (en) 2016-01-25 2018-08-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3448437B1 (en) 2016-04-29 2021-12-29 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
KR102623162B1 (ko) 2016-07-29 2024-01-11 리제너론 파아마슈티컬스, 인크. 통합된 전자 시각적 검사를 가진 조립 라인
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
HUE066064T2 (hu) 2016-08-18 2024-07-28 Regeneron Pharma Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
EP3515487B1 (en) 2016-09-23 2023-07-19 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
KR102605317B1 (ko) 2016-10-07 2023-11-24 리제너론 파아마슈티컬스, 인크. 실온 안정성 동결건조된 단백질
WO2018075798A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
IL312194A (en) 2016-10-25 2024-06-01 Regeneron Pharma Methods and systems for analysis of chromatography data
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
US11155574B2 (en) 2016-12-09 2021-10-26 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
US11292842B2 (en) 2017-02-21 2022-04-05 Regeneron Pharmaceuticals, Inc. Anti-PD-1 antibodies for treatment of lung cancer
KR102616820B1 (ko) 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018266324B2 (en) 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
BR112019027211A2 (pt) 2017-06-28 2020-06-30 Regeneron Pharmaceuticals, Inc. proteínas de ligação ao antígeno do papilomavírus anti-humano (hpv) e seus métodos de uso
CN114075269A (zh) 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
KR102584848B1 (ko) * 2017-08-18 2023-10-04 리제너론 파마슈티칼스 인코포레이티드 샘플 매트릭스에서 단백질 변이체를 분석하기 위한 이미지 모세관 등전 집속
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
CA3078974A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
US11460452B2 (en) 2017-12-13 2022-10-04 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TW202411650A (zh) 2018-02-01 2024-03-16 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP3774866A1 (en) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
AU2019262953A1 (en) 2018-04-30 2020-11-19 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202005985A (zh) 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
CA3103817A1 (en) 2018-07-02 2020-01-09 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
EP3837546A1 (en) 2018-08-13 2021-06-23 Regeneron Pharmaceuticals, Inc. Therapeutic protein selection in simulated in vivo conditions
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
CA3117539A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
EP3857237B1 (en) 2019-01-16 2023-03-01 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
CN113348364A (zh) 2019-01-25 2021-09-03 瑞泽恩制药公司 共同制剂中二聚体的定量和鉴别
AU2020212040A1 (en) 2019-01-25 2021-07-29 Regeneron Pharmaceuticals, Inc. Protein a chromatography - electrospray ionization mass spectrometer
EP3923978A1 (en) 2019-02-12 2021-12-22 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
EP3927435A1 (en) 2019-02-21 2021-12-29 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
AU2020231343A1 (en) 2019-03-06 2021-10-21 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
KR20210153102A (ko) 2019-04-17 2021-12-16 리제너론 파아마슈티컬스, 인크. 숙주세포 단백질의 확인
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
SG11202111262XA (en) 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
US20200363400A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Competitive Ligand Binding Assays
EP3986933A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
KR20220024035A (ko) 2019-06-21 2022-03-03 리제너론 파마슈티칼스 인코포레이티드 Muc16 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20220323937A1 (en) 2019-09-24 2022-10-13 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
JP2022550930A (ja) * 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2020397053A1 (en) * 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
KR20220147632A (ko) 2020-02-27 2022-11-03 리제너론 파아마슈티컬스, 인크. 활성 기반 숙주 세포 단백질 프로파일링
JP2023515941A (ja) 2020-02-28 2023-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法
IL296043A (en) 2020-03-06 2022-10-01 Regeneron Pharma Anti-gitro antibodies and their uses
JP2023519961A (ja) 2020-03-30 2023-05-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 低存在量の宿主細胞タンパク質を特徴付けるための方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
WO2021259200A1 (zh) 2020-06-22 2021-12-30 信达生物制药(苏州)有限公司 抗ang-2抗体及其用途
CN116390771A (zh) 2020-07-13 2023-07-04 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
MX2023000610A (es) 2020-07-16 2023-02-13 Raqualia Pharma Inc Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
BR112023000482A2 (pt) 2020-07-16 2023-01-31 Novartis Ag Anticorpos antibetacelulina, fragmentos dos mesmos e moléculas de ligação multiespecíficas
US20220064591A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
KR20230082038A (ko) 2020-10-02 2023-06-08 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 저하하는 암 치료용 항체 조합
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
IL302814A (en) 2020-11-10 2023-07-01 Regeneron Pharma Conjugates of antibody and selenium
CA3191141A1 (en) 2020-11-25 2022-06-02 Hunter Chen Sustained release formulations using non-aqueous membrane emulsification
JP2024500409A (ja) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質封入マイクロゲルの作製
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
CN116964088A (zh) 2021-01-25 2023-10-27 里珍纳龙药品有限公司 用于治疗肺动脉高压（pah）的抗pdgf-b抗体和使用方法
AU2022217058A1 (en) 2021-02-04 2023-09-21 Genuv Inc. Anti-pd-1 antibody and use thereof
IL304945A (en) 2021-02-11 2023-10-01 Regeneron Pharma Methods for treating cancer by administering a PD-1 inhibitor as adjuvant therapy
MX2023009774A (es) 2021-02-23 2023-10-30 Regeneron Pharma Metodos para tratar cancer de pulmon administrando un inhibidor de pd-1.
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
AU2022242000A1 (en) 2021-03-23 2023-09-14 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
MX2023010794A (es) 2021-03-26 2023-10-25 Regeneron Pharma Metodos y sistemas para el desarrollo de protocolos de mezcla.
MX2023014041A (es) 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
US20230018713A1 (en) 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
JP2024525715A (ja) 2021-07-13 2024-07-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 生物製剤の生成物関連バリアントを決定するための質量分析法ベースの戦略
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
KR20240053005A (ko) 2021-09-14 2024-04-23 리제너론 파아마슈티컬스, 인크. 생물학적 제제의 고분자량 종 특성화를 위한 nMass 분석 기반 전략
JP2024534638A (ja) 2021-09-28 2024-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 薬物濃度及び標的濃度を定量化するためのアッセイ
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
CA3236059A1 (en) 2021-11-01 2023-05-04 Regeneron Pharmaceuticals, Inc. Methods to prevent disulfide scrambling for ms-based proteomics
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
MX2024006187A (es) 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
AR127806A1 (es) 2021-12-01 2024-02-28 Kadmon Corp Llc Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024097642A1 (en) 2022-10-31 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024138000A1 (en) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
WO2024170773A1 (en) 2023-02-16 2024-08-22 Sanofi Cd40-binding proteins
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
EP0827544B1 (en) * 1995-05-23 2004-08-18 MorphoSys AG Multimeric proteins
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
WO1997042319A1 (fr) * 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOUVEAUX DERIVES DE L'ANTIGENE Fas
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
ES2273497T3 (es) 1998-06-15 2007-05-01 Gtc Biotherapeutics, Inc. Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
DE60041159D1 (de) * 1999-06-08 2009-01-29 Regeneron Pharma VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind.
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF

Also Published As

Publication number Publication date
US7279159B2 (en) 2007-10-09
TWI330197B (en) 2010-09-11
US7635474B2 (en) 2009-12-22
CY1111605T1 (el) 2015-10-07
KR101131429B1 (ko) 2012-07-27
PT1639007E (pt) 2009-06-04
US7087411B2 (en) 2006-08-08
IL172404A0 (en) 2006-04-10
ZA200600157B (en) 2007-04-25
PL1947118T3 (pl) 2011-05-31
RU2376373C2 (ru) 2009-12-20
EP1639007B1 (en) 2009-04-08
WO2005000895A3 (en) 2005-09-15
US20050043236A1 (en) 2005-02-24
CA2529660C (en) 2013-08-06
MY154826A (en) 2015-07-31
UA90657C2 (ru) 2010-05-25
EP1947118A1 (en) 2008-07-23
JP2007528708A (ja) 2007-10-18
TW200513532A (en) 2005-04-16
UA105625C2 (uk) 2014-06-10
CN1816566B (zh) 2011-01-12
SI1947118T1 (sl) 2011-02-28
US20100087632A1 (en) 2010-04-08
US20040014667A1 (en) 2004-01-22
UY28396A1 (es) 2004-11-08
ES2354847T3 (es) 2011-03-18
KR20060096184A (ko) 2006-09-08
CA2529660A1 (en) 2005-01-06
DK1947118T3 (da) 2011-02-07
AR044938A1 (es) 2005-10-12
IL204984A (en) 2011-12-29
RU2006102497A (ru) 2006-06-10
DE602004029833D1 (de) 2010-12-09
PT1947118E (pt) 2010-12-02
BRPI0412125A (pt) 2006-08-15
ES2323468T3 (es) 2009-07-16
WO2005000895A2 (en) 2005-01-06
CY1109204T1 (el) 2014-07-02
IL172404A (en) 2011-12-29
PL1639007T3 (pl) 2009-11-30
DE602004020474D1 (de) 2009-05-20
ATE427962T1 (de) 2009-04-15
HK1082511A1 (en) 2006-06-09
US20090062200A1 (en) 2009-03-05
NZ572107A (en) 2009-01-31
EP1639007A2 (en) 2006-03-29
ATE486091T1 (de) 2010-11-15
CN1816566A (zh) 2006-08-09
AU2004252175B2 (en) 2010-07-22
AU2004252175A1 (en) 2005-01-06
US7972598B2 (en) 2011-07-05
NO20060483L (no) 2006-03-28
MXPA05013641A (es) 2006-02-24
NZ544569A (en) 2008-12-24
NO339766B1 (no) 2017-01-30
JP2010246557A (ja) 2010-11-04
EP1947118B1 (en) 2010-10-27
SI1639007T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
DK1639007T3 (da) VEGF-fælder og terapeutiske anvendelser deraf
DK1641822T3 (da) Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
DK1513873T3 (da) Terapeutiske epitoper og anvendelser deraf
DK2418220T3 (da) Interferon-alpha-antistoffer og anvendelser deraf
DK1519770T3 (da) Elektroporesisk indretning og indsprøjtningsapparat
DK1572744T3 (da) Immunoglobulinvarianter og deres anvendelser
DE602004030308D1 (de) HF-Messer und Endoskopiegerät
NO20040640L (no) Anordning og fremgangsmate
BR0308476B1 (pt) dispositivo anastomàtico
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
DE602004015901D1 (de) Fühlvorrichtung und Fühlschaltung
DE60230583D1 (de) Spielvorrichtung und Spielprogramm
DE60328923D1 (de) Codeerkennungsverfahren und einrichtung
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
ITMI20031145A0 (it) Dispositivo e procedimento di cottura
DE602004024999D1 (de) Thermotherapie-vorrichtung
DK1663291T3 (da) Rekombinante lubricinmolekyler og anvendelser deraf
FI20030261A (fi) Iskulaite
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
DK1506291T3 (da) Nye phospholipaser og anvendelser deraf
ATA13602003A (de) Therapeutisches behandlungsgerät